As the COVID-19 pandemic reshaped the global economy, some pharma companies coped better than others. The who and why offer some hints about who's best suited to weather a future crisis.
That's the word from analysts at Jefferies, which dug into the numbers to assess COVID-19's effects on the industry so far.
The bad news? Certain products “suffered disproportionately." That list includes GlaxoSmithKline’s shingles vaccine Shingrix, Novartis’ spinal muscular atrophy gene therapy Zolgensma, Novo Nordisk’s new oral diabetes drug Rybelsus, and Roche’s hemophilia drug Hemlibra, the analysts wrote. Biogen's spinal muscular atrophy drug Spinraza also took a pandemic hit, executives acknowledged.